Valuation Abbott Laboratories Wiener Boerse
Stocks
ABT
US0028241000
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 88.10 EUR | +1.45% |
|
+7.07% | -16.86% |
| 11:18pm | Abbott investigates two separate cyber incidents, says no operations affected | RE |
| 07-17 | Abbott Laboratories Seen on Track for H2 Growth Acceleration, RBC Says | MT |
Company Valuation: Abbott Laboratories
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 241,365 | 191,427 | 191,088 | 196,184 | 217,859 | 175,366 | - | - |
| Change | - | -20.69% | -0.18% | 2.67% | 11.05% | -19.5% | - | - |
| Enterprise Value (EV) 1 | 249,166 | 198,318 | 198,871 | 202,693 | 222,266 | 198,747 | 191,110 | 187,306 |
| Change | - | -20.41% | 0.28% | 1.92% | 9.66% | -10.58% | -3.84% | -1.99% |
| P/E | 35.7x | 28.1x | 33.8x | 14.8x | 33.7x | 27.4x | 21.7x | 19.1x |
| PBR | 6.93x | 5.2x | 4.94x | 4.11x | 4.18x | 4.34x | 3.41x | 3.18x |
| PEG | - | -36.9x | -2x | 0x | -0.7x | -23.97x | 0.8x | 1.4x |
| Capitalization / Revenue | 5.6x | 4.39x | 4.76x | 4.68x | 4.91x | 3.49x | 3.21x | 2.99x |
| EV / Revenue | 5.78x | 4.54x | 4.96x | 4.83x | 5.01x | 3.95x | 3.5x | 3.2x |
| EV / EBITDA | 19.4x | 15.9x | 19.5x | 19.1x | 18.9x | 15.2x | 13.1x | 11.8x |
| EV / EBIT | 22x | 17.7x | 22.3x | 21.8x | 21.6x | 17x | 14.7x | 13.1x |
| EV / FCF | 28.8x | 25.4x | 39.3x | 31.9x | 30.1x | 25.1x | 20.4x | 18.3x |
| FCF Yield | 3.47% | 3.94% | 2.54% | 3.13% | 3.33% | 3.99% | 4.9% | 5.45% |
| Dividend per Share 2 | 1.82 | 1.92 | 2.08 | 2.24 | 2.4 | 2.587 | 2.718 | 2.858 |
| Rate of return | 1.29% | 1.75% | 1.89% | 1.98% | 1.92% | 2.57% | 2.7% | 2.84% |
| EPS 2 | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 | 3.677 | 4.646 | 5.284 |
| Distribution rate | 46.2% | 49.1% | 63.8% | 29.3% | 64.5% | 70.3% | 58.5% | 54.1% |
| Net sales 1 | 43,075 | 43,653 | 40,109 | 41,950 | 44,328 | 50,318 | 54,634 | 58,566 |
| EBITDA 1 | 12,815 | 12,485 | 10,188 | 10,635 | 11,735 | 13,076 | 14,537 | 15,820 |
| EBIT 1 | 11,324 | 11,231 | 8,911 | 9,295 | 10,301 | 11,716 | 13,031 | 14,322 |
| Net income 1 | 7,071 | 6,933 | 5,723 | 13,402 | 6,524 | 6,621 | 8,161 | 9,211 |
| Net Debt 1 | 7,801 | 6,891 | 7,783 | 6,509 | 4,407 | 23,381 | 15,744 | 11,941 |
| Reference price 2 | 140.74 | 109.79 | 110.07 | 113.11 | 125.29 | 100.68 | 100.68 | 100.68 |
| Nbr of stocks (in thousands) | 1,714,968 | 1,743,574 | 1,736,059 | 1,734,455 | 1,738,834 | 1,741,813 | - | - |
| Announcement Date | 26/01/22 | 25/01/23 | 24/01/24 | 22/01/25 | 22/01/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 18.88x | 3.31x | 11.62x | 3.57% | 106B | |
| 17.13x | 0.19x | 12.1x | 0.77% | 59.91B | |
| 31.81x | 7.73x | 20.21x | 1.26% | 51.95B | |
| 39.41x | 3.13x | 10.67x | 2.43% | 43.58B | |
| 38.15x | 1.39x | 12.22x | 0.26% | 33.65B | |
| 31.31x | 5.58x | 17.8x | -.--% | 29.58B | |
| 42.57x | 7.44x | 26.86x | 0.24% | 25.31B | |
| 23.96x | 3.5x | 12.59x | 1.21% | 21.23B | |
| 47.21x | 6.34x | 20.38x | 0.46% | 20.68B | |
| Average | 32.27x | 4.29x | 16.05x | 1.13% | 43.6B | |
| Weighted average by Cap. | 28.49x | 3.84x | 14.74x | 1.65% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ABT Stock
- ABT Stock
- Valuation Abbott Laboratories
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
